Tan, Y., Liu, K., Zhu, C., Wang, S., Wang, Y., Xue, J., . . . Zhao, H. (2024). Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer. Cancer Immunology, Immunotherapy, 73(12), . https://doi.org/10.1007/s00262-024-03831-1
Chicago-referens (17:e uppl.)Tan, Yang, et al. "Efficacy and Safety of Lenvatinib Combined with Anti-PD-1 Antibodies Plus GEMOX Chemotherapy as Non-first-line Systemic Therapy in Advanced Gallbladder Cancer." Cancer Immunology, Immunotherapy 73, no. 12 (2024). https://doi.org/10.1007/s00262-024-03831-1.
MLA-referens (9:e uppl.)Tan, Yang, et al. "Efficacy and Safety of Lenvatinib Combined with Anti-PD-1 Antibodies Plus GEMOX Chemotherapy as Non-first-line Systemic Therapy in Advanced Gallbladder Cancer." Cancer Immunology, Immunotherapy, vol. 73, no. 12, 2024, https://doi.org/10.1007/s00262-024-03831-1.
